Skip to main content
Erschienen in: Journal of Nuclear Cardiology 6/2021

06.02.2019 | Editorial

New insights for early assessment of cardiac involvement in Anderson-Fabry disease

verfasst von: Alberto Cuocolo, MD, Carmela Nappi, MD, Valeria Gaudieri, MD, PhD, Antonio Pisani, MD, PhD, Massimo Imbriaco, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Excerpt

Anderson-Fabry disease (AFD) is an X-linked recessive lysosomal storage disorder that is caused by the deficient activity of a-galactosidase A (a-Gal A)1 with the resultant accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids2 in a variety of cells, including micro-vascular endothelial cells, renal tubular cells, and myocardial cells. In classically affected males, the progressive Gb3 accumulation leads to renal, cardiac, and cerebro-vascular manifestations and early death.3 Chronic renal failure represents the most frequent cause of morbidity, with cardiac involvement being the leading cause of death and premature mortality.4 It has been reported that the progressive accumulation of Gb3 in cardiomyocytes, cardiac valves, endothelial cells, and conduction system, leads to increased ventricular wall thickness and functional impairment,5 in addition to valvular and electrocardiographic abnormalities.6 The classic cardiac involvement is a form of hypertrophic cardiomyopathy, usually described as concentric left ventricular hypertrophy (LVH). The disease is progressive, with symptoms appearing with increasing age. …
Literatur
1.
Zurück zum Zitat Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill; 2001. p. 3733–74. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill; 2001. p. 3733–74.
3.
Zurück zum Zitat Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. European FOS investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228–35. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. European FOS investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228–35.
4.
Zurück zum Zitat Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, et al. The kidney in Fabry’s disease. Clin Genet. 2014;86:301–9.CrossRef Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, et al. The kidney in Fabry’s disease. Clin Genet. 2014;86:301–9.CrossRef
5.
Zurück zum Zitat Spinelli L, Nicolai E, Acampa W, Imbriaco M, Pisani A, Rao MA, et al. Cardiac performance during exercise in patients with Fabry’s disease. Eur J Clin Invest. 2008;38:910–7.CrossRef Spinelli L, Nicolai E, Acampa W, Imbriaco M, Pisani A, Rao MA, et al. Cardiac performance during exercise in patients with Fabry’s disease. Eur J Clin Invest. 2008;38:910–7.CrossRef
6.
Zurück zum Zitat Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C, et al. Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart. 2016;102:298–302.CrossRef Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C, et al. Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart. 2016;102:298–302.CrossRef
7.
Zurück zum Zitat Weidemann F, Sanchez-Niño MD, Politei J, Oliveira JP, Wanner C, Warnock DG, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.CrossRef Weidemann F, Sanchez-Niño MD, Politei J, Oliveira JP, Wanner C, Warnock DG, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.CrossRef
8.
Zurück zum Zitat Krämer J, Niemann M, Liu D, Hu K, MacHann W, Beer M, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J. 2013;34:1587–96.CrossRef Krämer J, Niemann M, Liu D, Hu K, MacHann W, Beer M, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J. 2013;34:1587–96.CrossRef
9.
Zurück zum Zitat Imbriaco M, Spinelli L, Cuocolo A, Maurea S, Sica G, Quarantelli M, et al. MRI characterization of myocardial tissue in patients with Fabry’s disease. AJR Am J Roentgenol. 2007;188:850–3.CrossRef Imbriaco M, Spinelli L, Cuocolo A, Maurea S, Sica G, Quarantelli M, et al. MRI characterization of myocardial tissue in patients with Fabry’s disease. AJR Am J Roentgenol. 2007;188:850–3.CrossRef
10.
Zurück zum Zitat Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart. 2009;95:1103–7.CrossRef Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart. 2009;95:1103–7.CrossRef
11.
Zurück zum Zitat Imbriaco M, Messalli G, Avitabile G, Cuocolo A, Maurea S, Soscia F, et al. Cardiac magnetic resonance imaging illustrating Anderson-Fabry disease progression. Br J Radiol. 2010;83:e249–51.CrossRef Imbriaco M, Messalli G, Avitabile G, Cuocolo A, Maurea S, Soscia F, et al. Cardiac magnetic resonance imaging illustrating Anderson-Fabry disease progression. Br J Radiol. 2010;83:e249–51.CrossRef
12.
Zurück zum Zitat Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5.
13.
Zurück zum Zitat Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479–82.CrossRef Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479–82.CrossRef
14.
Zurück zum Zitat Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903.CrossRef Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903.CrossRef
15.
Zurück zum Zitat Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–21.CrossRef Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–21.CrossRef
16.
Zurück zum Zitat Stirrat J, White JA. The prognostic role of late gadolinium enhancement magnetic resonance imaging in patients with cardiomyopathy. Can J Cardiol. 2013;29:329–36.CrossRef Stirrat J, White JA. The prognostic role of late gadolinium enhancement magnetic resonance imaging in patients with cardiomyopathy. Can J Cardiol. 2013;29:329–36.CrossRef
17.
Zurück zum Zitat Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: Consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4:592–601.CrossRef Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: Consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4:592–601.CrossRef
18.
Zurück zum Zitat Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;5(16):99.CrossRef Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;5(16):99.CrossRef
19.
Zurück zum Zitat Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance non-contrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–8.CrossRef Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance non-contrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–8.CrossRef
20.
Zurück zum Zitat Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, et al. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2015;42:1025–31.CrossRef Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, et al. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2015;42:1025–31.CrossRef
21.
Zurück zum Zitat Spinelli L, Imbriaco M, Nappi C, Nicolai E, Giugliano G, Ponsiglione A, et al. Early cardiac involvement affects left ventricular longitudinal function in females carrying α-galactosidase A mutation: Role of hybrid positron emission tomography and magnetic resonance imaging and speckle-tracking echocardiography. Circ Cardiovasc Imaging. 2018;11:e007019.PubMed Spinelli L, Imbriaco M, Nappi C, Nicolai E, Giugliano G, Ponsiglione A, et al. Early cardiac involvement affects left ventricular longitudinal function in females carrying α-galactosidase A mutation: Role of hybrid positron emission tomography and magnetic resonance imaging and speckle-tracking echocardiography. Circ Cardiovasc Imaging. 2018;11:e007019.PubMed
22.
Zurück zum Zitat Frustaci A, Verardo R, Grande C, Galea N, Piselli P, Carbone I, et al. Immune-mediates myocarditis in Fabry disease cardiomyopathy. J Am Heart Assoc. 2018;7:e009052.PubMedPubMedCentral Frustaci A, Verardo R, Grande C, Galea N, Piselli P, Carbone I, et al. Immune-mediates myocarditis in Fabry disease cardiomyopathy. J Am Heart Assoc. 2018;7:e009052.PubMedPubMedCentral
23.
Zurück zum Zitat Verschure DO, Lutter R, van Eck-Smit BL, Somsen GA, Verberne HJ. Myocardial 123I-MIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure. J Nucl Cardiol. 2018;25:845–53.CrossRef Verschure DO, Lutter R, van Eck-Smit BL, Somsen GA, Verberne HJ. Myocardial 123I-MIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure. J Nucl Cardiol. 2018;25:845–53.CrossRef
24.
Zurück zum Zitat Spinelli L, Pellegrino T, Pisani A, Giudice CA, Riccio E, Imbriaco M, et al. Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123) I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2016;43:729–39.CrossRef Spinelli L, Pellegrino T, Pisani A, Giudice CA, Riccio E, Imbriaco M, et al. Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123) I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2016;43:729–39.CrossRef
25.
Zurück zum Zitat Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Ponsiglione A, Nappi C, et al. Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2017;44:2266–73.CrossRef Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Ponsiglione A, Nappi C, et al. Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2017;44:2266–73.CrossRef
Metadaten
Titel
New insights for early assessment of cardiac involvement in Anderson-Fabry disease
verfasst von
Alberto Cuocolo, MD
Carmela Nappi, MD
Valeria Gaudieri, MD, PhD
Antonio Pisani, MD, PhD
Massimo Imbriaco, MD
Publikationsdatum
06.02.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 6/2021
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-019-01635-w

Weitere Artikel der Ausgabe 6/2021

Journal of Nuclear Cardiology 6/2021 Zur Ausgabe

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Beutel versus Maschine: Beste Beatmungstechnik bei Herzstillstand gesucht

02.05.2024 Kardiopulmonale Reanimation Nachrichten

Stehen die Chancen auf eine Rückkehr der Spontanzirkulation nach Herz-Kreislauf-Stillstand bei manueller oder maschineller Beatmung besser? Und unterscheidet sich das neurologische Outcome nach der Reanimation? Das belgische Herzstillstand-Register liefert die Daten für einen direkten Vergleich zwischen Beutel und Beatmungsgerät.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.